Bristol-Myers Squibb Company
$ 64.72
0.89%
07 Aug - close price
- Market Cap 132,204,495,000 USD
- Current Price $ 64.72
- High / Low $ 64.73 / 63.79
- Stock P/E 14.26
- Book Value 10.93
- EPS 4.54
- Next Earning Report -
- Dividend Per Share $2.51
- Dividend Yield 3.91 %
- Next Dividend Date -
- ROA 0.11 %
- ROE 0.47 %
- 52 Week High 68.10
- 52 Week Low 41.13
About
Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
Analyst Target Price
$66.21
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-30 | 2026-04-30 | 2026-02-05 | 2025-10-30 | 2025-07-31 | 2025-04-24 | 2025-02-06 | 2024-10-31 | 2024-07-26 | 2024-04-25 | 2024-02-02 | 2023-10-26 |
| Reported EPS | 2.04 | 1.58 | 1.26 | 1.63 | 1.46 | 1.8 | 1.67 | 1.8 | 2.07 | -4.4 | 1.59 | 2 |
| Estimated EPS | 1.59 | 1.42 | 1.2 | 1.52 | 1.1 | 1.5 | 1.47 | 1.5 | 1.63 | -4.14 | 1.43 | 1.77 |
| Surprise | 0.45 | 0.16 | 0.06 | 0.11 | 0.36 | 0.3 | 0.2 | 0.3 | 0.44 | -0.26 | 0.16 | 0.23 |
| Surprise Percentage | 28.3019% | 11.2676% | 5% | 7.2368% | 32.7273% | 20% | 13.6054% | 20% | 26.9939% | -6.2802% | 11.1888% | 12.9944% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Aug 2026 | May 2026 | Feb 2026 | Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 | May 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-08-03 | 2026-05-01 | 2026-02-02 | 2025-11-03 | 2025-08-01 | 2025-05-01 | 2025-02-03 | 2024-11-01 | 2024-08-01 | 2024-05-01 |
| Amount | $0.63 | $0.63 | $0.63 | $0.62 | $0.62 | $0.62 | $0.62 | $0.6 | $0.6 | $0.6 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BMY
2026-08-08 01:10:42
This article provides a comprehensive profile of the Pacer US Cash Cows 100 ETF (COWZ), detailing its investment strategy, key statistics, holdings, and dividend information. COWZ focuses on broad-based US large-cap equities with a strategy centered on companies exhibiting high free cash flow. The ETF has assets under management of $19.04 billion and an expense ratio of 0.49%.
2026-08-07 23:11:28
Alto Neuroscience Inc. (ANRO) stock reached an all-time high of $29.34, reflecting an 840.52% increase over the past year, though InvestingPro analysis suggests it may be overvalued due to unprofitability. The company recently priced a $100 million stock offering and published positive clinical trial results in Nature Medicine for a mood disorder treatment. H.C. Wainwright reiterated a Buy rating with a $50.00 price target, and the company appointed Andrew Miller, Ph.D., to its Board of Directors, signaling continued strategic and research advancements.
2026-08-07 22:41:19
An Argus report dated August 5, 2026, raises the target price for Cameco Corporation (CCJ) to $105.00, citing the company as a provider of uranium for clean energy. The current price of CCJ is $97.39. The report is exclusive to Yahoo Finance Silver subscribers, offering detailed company profiles and trade insights.
2026-08-07 22:40:17
The California State Teachers Retirement System increased its stake in Xenon Pharmaceuticals Inc. by 64% in the first quarter, purchasing 36,183 additional shares to bring its total holding to 92,747 shares valued at approximately $5.4 million. Institutional investors now own 95.45% of the company, and analysts maintain a consensus "Buy" rating with an average price target of $77.20. The biopharmaceutical company recently reported a quarterly loss of $1.11 per share, outperforming analyst expectations.
2026-08-07 19:39:53
This Yahoo Finance page provides a comprehensive overview of Prothena Corporation plc (PRTA) stock, including its current price, historical data, and key financial metrics. It details the company's clinical-stage biotechnology pipeline, focusing on therapies for protein dysregulation diseases, and offers analyst insights and performance comparisons.
2026-08-07 19:39:53
Prothena Corporation plc reported its second quarter and first six months 2026 financial results, highlighting a net cash used in operating and investing activities of $25.7 million for the quarter and a net cash provided of $3.2 million for the first six months. The company updated its year-end cash guidance to approximately $259 million (midpoint) and provided updates on its partnered clinical programs, including prasinezumab for Parkinson's disease, coramitug for ATTR amyloidosis with cardiomyopathy, and moponetug for Alzheimer's disease, which collectively represent up to $3 billion in future milestone payments. Prothena also detailed its active preclinical pipeline and financial performance, including a significant reduction in net loss compared to the previous year.
